No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PROK ProKidney
- 4.200
- +0.240+6.06%
Close May 30 16:00 ET
268.48MMarket Cap-7368P/E (TTM)
4.275High3.900Low675.50KVolume3.950Open3.960Pre Close2.82MTurnover1.55%Turnover RatioLossP/E (Static)63.92MShares13.51052wk High-0.24P/B182.61MFloat Cap1.12052wk Low--Dividend TTM43.48MShs Float14.190Historical High--Div YieldTTM9.47%Amplitude1.120Historical Low4.170Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
ProKidney Phase 2 Trial Success Sparks Investor Interest
ProKidney to Participate in the Jefferies Global Healthcare Conference
WINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced
ProKidney Is Maintained at Neutral by B of A Securities
ProKidney Is Maintained at Neutral by B of A Securities
B of A Securities Maintains Neutral on ProKidney, Raises Price Target to $4
B of A Securities analyst Jason Gerberry maintains ProKidney (NASDAQ:PROK) with a Neutral and raises the price target from $3 to $4.
ProKidney Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/29/2024 2.86% B of A Securities $3 → $4 Maintains Neutral 03/07/2024 -22.86% Morgan Stanley → $3 Assume
Buy Rating Affirmed for ProKidney on Rilparencel's Promising Efficacy in CKD Treatment
Comments
$ProKidney(PROK.US$
NEWS
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
NEWS
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
Wall Street's meme-stock madness extended to more companies Tuesday, with $ProKidney(PROK.US$ and other names rising more than 25% despite no apparent news.
ProKidney -- a volatile biotech that's developing kidney-disease treatments – gained 33.8% to close at $4.12 even though the company had no news or other no obvious catalysts for the rally.
The stock has had a volatile history ever since going public in 2...
ProKidney -- a volatile biotech that's developing kidney-disease treatments – gained 33.8% to close at $4.12 even though the company had no news or other no obvious catalysts for the rally.
The stock has had a volatile history ever since going public in 2...
7
2
$ProKidney(PROK.US$ sank more than 15% Thursday as the biotech snapped a five-session winning streak that saw its price rise some 130% in just days.
PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news.
Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday.
ProKidney, which is trying t...
PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news.
Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday.
ProKidney, which is trying t...
7
$ProKidney(PROK.US$ rose more than 30% Tuesday as the biotech firm rallied for the fourth straight session – a run-up that's seen the stock rise nearly 90% in less than a week.
PROK gained 30.1% to close at $2.72, up 87.6% from last Wednesday's close at $1.45.
ProKidney has been soaring despite no news announcements, although the stock's rally began the day after $Vertex Pharmaceuticals(VRTX.US$ unveiled plans to buy biotech $Alpine Immune(ALPN.US$ for $4.9 ...
PROK gained 30.1% to close at $2.72, up 87.6% from last Wednesday's close at $1.45.
ProKidney has been soaring despite no news announcements, although the stock's rally began the day after $Vertex Pharmaceuticals(VRTX.US$ unveiled plans to buy biotech $Alpine Immune(ALPN.US$ for $4.9 ...
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg